

IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS

A. Rodriguez, X. Fernández, A. Arderiu, O. Fando, S. Pineda, J. Urbina, M. Berzosa, D. Conde
Hospital del Mar (PSMar), Pharmacy, Barcelona, Spain

Key words:

telepharmacy, oral antineoplastics, community-pharmacy remote-dispensing, SARS-CoV-2

Abstract number: 1ISG-003

Background and importance

Oral antineoplastic agents (OAA) are dispensed through hospital pharmacy service. COVID-19 restrictions have accelerated implantation of alternative ways of remote dispensation and pharmaceutical care to minimize patients' virus exposition.

Aim and objectives: To describe results from the implementation of OAA-remote-dispensing program and telepharmacy to cancer patients.

Material and methods

Observational prospective study from October 2020 to April 2021 in a 400-bed university hospital.

Patients received virtual pharmaceutical care and agreed to collect medication at their nearest community pharmacy. A follow-up visit was made by telephone scoring level of satisfaction (1 to 10).

Treatment Satisfaction Questionnaire for Medication II (TSQM v.II) was also employed. Adherence was graded from 1 to 3 depending on number of missed doses, meaning 1 none and 3 more than 4 missed administrations.

Results


44 patients benefit from telepharmacy, 15 (34%) women, age 63 (42-86) years, performance status 0: 37 (84%).

Adherence grade 1: 35 (79%), grade 2: 9 (20%).

Level of satisfaction with treatment delivery 10 (8-10).

OAA: 9 (20%) palbociclib, 7 (16%) ribociclib, 3 (7%) capecitabine, 3 (7%) nilotinib, 3 (7%) alpelisib.

Pharmacy interventions	Frequency (%)
Administration errors	3 (6.8)
New concomitant medication	23 (52.3)
Potential interactions with OAA	2 (4.5)
Alternative medicine (AM)	12 (27.3)
Interactions with AM	5 (11.4)
Storage errors	1 (2.3)
Adverse effects	29 (65.9)
- Gastrointestinal	12 (26.7)
- Fatigue	12 (26.7)
- Central nervous system	7 (15.6)
- Dermatologic	5 (11.1)
Resolved doubts	15 (34.1)



Positive correlations		Rho (p-value)	Negative correlations		Rho (p-value)
Treatment duration	Effectivity	0.308 (0.042)	Adherence	Adverse effects	0.419 (0.005)
			Treatment duration	Convenience	0.454 (0.002)
			Treatment duration	Global satisfaction	0.350 (0.02)

Conclusion and relevance

Level of satisfaction with telepharmacy and remote delivery is very high.

Patients with more adverse effects present less treatment adherence.

Patients with more treatment duration think that their treatment is more effective, but the less duration the more level of satisfaction.